🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are on the rise globally, with figures suggesting more than 82 million infections each year. Particularly high rates are seen in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Receive Clearance

Zoliflodacin, marketed under the name a brand name, was authorized by the US FDA in recent days for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This treatment, which is employed against urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to see it through.

“This approval represents a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

Based on data detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which combines two antibiotics. The research included nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in numerous developing nations.

Doctors directly involved have shared hope. Having a single-dose, oral treatment such as this is hailed as a "revolutionary step" for gonorrhoea control. This is considered essential to reduce the burden of the disease for patients and to prevent the spread of untreatable gonorrhoea around the world.